Clinical Efficacy and Parameters Affecting the Response to Dulaglutide Treatment in Patients with Type 2 Diabetes: A Retrospective, Real-World Data Study

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia

(2019) Ju-Ming Lu   ADVANCES IN THERAPY

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post hoc analyses of a randomized, double‐blind, phase 3 study

(2019) Li Xin Shi et al.   Journal of Diabetes Investigation

Pharmacologic Glycemic Management of Type 2 Diabetes in Adults

(2018) Lorraine Lipscombe et al.   Canadian Journal of Diabetes

Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment

(2018) Reema Mody et al.   CURRENT MEDICAL RESEARCH AND OPINION

Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration

(2018) Kevin M. Pantalone et al.   DIABETES OBESITY & METABOLISM

Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme

(2018) Chantal Mathieu et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data

(2018) Anne Kugler et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Diabetes Fact Sheet in Korea, 2016: An Appraisal of Current Status

(2018) Jong Chul Won et al.   Diabetes & Metabolism Journal

Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis

(2018) Hiroyuki Inoue et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019

(2018)   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

(2018) Stephen C. Bain et al.   DIABETES OBESITY & METABOLISM

Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes

(2017) Noriyuki Iwamoto et al.   Diabetes Therapy

Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes

(2017) Noriyuki Iwamoto et al.   Diabetes Therapy

Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and

(2016) M. A. Boustani et al.   DIABETES OBESITY & METABOLISM

Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes

(2016) Carol Wysham et al.   DIABETES OBESITY & METABOLISM

A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)

(2016) K. M. Dungan et al.   DIABETES OBESITY & METABOLISM

Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

(2016) Zhixia Li et al.   PLoS One

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

(2015) Francesco Giorgino et al.   DIABETES CARE

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial

(2015) A. Ahmann et al.   DIABETES OBESITY & METABOLISM

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

(2014) Julio Rosenstock et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

(2014) Michael Nauck et al.   DIABETES CARE

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

(2014) Kathleen M Dungan et al.   LANCET

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

(2012) G. Grunberger et al.   DIABETIC MEDICINE

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study

(2011) G. E. Umpierrez et al.   DIABETES OBESITY & METABOLISM